Neurofilament light chain (NfL) is a stronger biomarker for progression and brain atrophy than mutant huntingtin (mHTT) in Huntington’s disease (HD) and could be used to inform clinical trial design, specialists have reported.
Neurofilament light chain (NfL) is a stronger biomarker for progression and brain atrophy than mutant huntingtin (mHTT) in Huntington’s disease (HD) and could be used to inform clinical trial design, specialists have reported.